Our study had limited information on dipeptidyl peptidase 4 inhibitors, which have the highest prescription rate as a first-line treatment for T2DM in Japan [34], or on renin–angiotensin system inhibitors, which exert reno-protective effects [35]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.